Pyrogen Considerations and Strategy for the Development of Virus-Like Particles

Posted on September 9, 2024

Aleksandra Moleda, Senior Development Scientist
Callum Scott, Technical Transfer & Formulations Development Manager
Murray A. Skinner, Chief Scientific Officer and Executive Director
Allergy Therapeutics
Martin F Bachmann, Professor of Immunology
Department of BioMedical Research, University of Bern, Bern, Switzerland

Introduction Virus-like particles (VLPs) are versatile entities which have been used to successfully develop novel vaccines towards infectious agents, notably Hepatitis B and Human Papilloma virus1-4. Resembling native viruses, VLPs are highly immunogenic and can induce strong immune responses, albe...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy

Subscribe to our FREE newsletter
and WEBINAR UPDATES